Finance

Beta
Lists
INO:BMV
Inovio Pharmaceuticals Inc
MX$22.00
0.00%
(0.00) 1D
May 27, 10:52:01 AM GMT-6  ·   MXN
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Mkt. cap
89.68M
Avg. vol.
31.00
Volume
0.00
52-wk high
MX$57.00
52-wk low
MX$20.00
No. of employees
112
Mkt. cap
89.68M
Avg. vol.
31.00
Volume
0.00
52-wk high
MX$57.00
52-wk low
MX$20.00
No. of employees
112
News stories
From sources across the web
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
SectorBiotechnology
Websiteinovio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
14.52M
13.33M
10.26M
-
Cost of revenue
14.52M
13.33M
10.26M
-
Research and development expenses
-
-
-
14.07M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.56M
7.88M
7.22M
7.88M
Operating expense
8.56M
7.88M
7.22M
21.95M
Total operating expenses
23.08M
21.21M
17.48M
21.95M
Operating income
-23.08M
-21.21M
-17.48M
-21.95M
Other non operating income
-1.87M
-24.27M
21.17M
3.85M
EBT including unusual items
-23.52M
-45.50M
3.76M
-19.68M
EBT excluding unusual items
-23.57M
-45.52M
3.75M
-19.76M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23.52M
-45.50M
3.76M
-19.68M
Net profit margin
-
-
-
-
Earnings per share
-0.61
-0.87
-0.28
-0.31
Interest and investment income
610.64K
552.11K
449.34K
439.59K
Interest expense
-
-
-
-
Net interest expenses
610.64K
552.11K
449.34K
439.59K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.73M
-20.86M
-17.14M
-21.63M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer